Mirtazapine (Remeron) is a NaSSA (Noradrenergic and Specific Serotonergic Antidepressant) used to treat major depressive disorder and commonly prescribed off-label for insomnia, anxiety, and appetite stimulation in cancer or HIV patients. It works by blocking alpha-2 adrenergic autoreceptors to increase norepinephrine and serotonin release, while also antagonizing H1, 5-HT2A, 5-HT2C, and 5-HT3 receptors. Common side effects include pronounced sedation and significant weight gain — both most prominent at lower doses — with notably less sexual dysfunction and nausea than SSRIs. It carries a black box warning for increased suicidality in patients under 25.
Mirtazapine
Uses & FDA Indications
Mirtazapine occupies a distinct niche among antidepressants — its receptor profile is entirely different from SSRIs and SNRIs, giving it a complementary set of clinical advantages and a predictably different side effect burden. It is often chosen when sleep disturbance, poor appetite, nausea, or sexual dysfunction from prior antidepressants are central concerns.
The sole FDA-approved indication is major depressive disorder (MDD) in adults. Its efficacy is well-established across multiple randomized trials, with some meta-analyses suggesting a slight advantage in speed of onset and response rate compared to SSRIs, though SSRIs are generally preferred first-line due to the side effect profile.
Off-label uses include: insomnia (frequently prescribed at low doses as a sleep aid even in non-depressed patients), generalized anxiety disorder and PTSD (particularly when sleep disruption is prominent), appetite stimulation in cancer patients, HIV-associated wasting, elderly patients with poor appetite, and chemotherapy-induced nausea (the 5-HT3 antagonism provides genuine antiemetic activity, comparable mechanistically to ondansetron).
How It Works
Mirtazapine is classified as a NaSSA — Noradrenergic and Specific Serotonergic Antidepressant. Unlike SSRIs and SNRIs that block monoamine reuptake transporters, mirtazapine increases neurotransmitter release by blocking inhibitory autoreceptors and selectively antagonizing specific serotonin receptor subtypes.
The core mechanism is alpha-2 adrenergic receptor antagonism. Alpha-2 receptors on noradrenergic and serotonergic neurons act as "brakes" — when activated by norepinephrine, they reduce further release. By blocking these autoreceptors, mirtazapine removes this feedback inhibition, resulting in increased release of both norepinephrine and serotonin into synapses. More serotonin is released — but mirtazapine simultaneously blocks 5-HT2A, 5-HT2C, and 5-HT3 serotonin receptors, directing serotonergic activity specifically through 5-HT1A receptors (associated with antidepressant and anxiolytic effects) while avoiding the receptor subtypes responsible for anxiety, insomnia, and sexual dysfunction that SSRIs non-selectively activate.
Additionally: H1 (histamine-1) blockade causes sedation and appetite increase; 5-HT3 antagonism reduces nausea and contributes to antiemetic properties; 5-HT2C antagonism contributes to appetite increase and weight gain.
The paradox of mirtazapine sedation: at lower therapeutic levels, H1 (histamine) blockade dominates the clinical picture — causing pronounced sedation and appetite stimulation. At higher levels, the noradrenergic activation (from alpha-2 blockade) increasingly counteracts H1-mediated sedation, resulting in less net sedation. Clinicians sometimes deliberately exploit this: using a low dose specifically for insomnia or appetite stimulation, and increasing the dose when sedation becomes problematic rather than reducing it.
FDA BLACK BOX WARNING — SUICIDALITY IN YOUTH: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25) with major depressive disorder and other psychiatric disorders. Monitor closely for clinical worsening and emergence of suicidal ideation, especially during the first 1–2 months of treatment and after dose changes. Mirtazapine is not approved for use in pediatric patients.
Side Effects
Common
- Sedation / somnolence — one of the most common effects, especially at lower doses; often desired therapeutically but limits daytime functioning; take at bedtime to minimize impact
- Increased appetite and weight gain — very common and often significant; driven by H1 and 5-HT2C antagonism; among the most pronounced weight gain of any antidepressant
- Dry mouth — anticholinergic-like effect
- Constipation
- Dizziness — particularly on standing (mild orthostatic hypotension)
Advantages Over SSRIs
- Sexual dysfunction — substantially less than SSRIs; may actually improve sexual function in some patients transitioning from SSRIs
- Nausea — considerably less nausea than SSRIs due to 5-HT3 antagonism; often preferred in patients who are nausea-sensitive
- Insomnia — improves sleep architecture rather than disrupting it (contrast with SSRI-induced insomnia)
Serious (Rare)
- Agranulocytosis — rare but potentially life-threatening reduction in white blood cells; monitor for signs of infection (fever, sore throat, mouth sores); discontinue if suspected and obtain CBC
- QTc prolongation — mild; clinically relevant primarily in combination with other QT-prolonging drugs
- Serotonin syndrome — risk exists with concurrent serotonergic drugs, particularly MAOIs; lower intrinsic risk than SSRIs due to its distinct mechanism
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue) | Combination raises serotonin syndrome risk. Classic MAOIs and mirtazapine cannot be used concurrently or within 14 days of each other in either direction. | CONTRAINDICATED — absolute |
| CNS Depressants (alcohol, benzodiazepines, opioids, sleep medications) | Additive CNS depression and sedation; significantly amplifies mirtazapine's intrinsic sedating effect; raises respiratory depression risk with opioids. | High — minimize combination; counsel patients to avoid alcohol especially at treatment initiation |
| Serotonergic drugs (SSRIs, SNRIs, tramadol, triptans, St. John's Wort) | Additive serotonergic activity raises serotonin syndrome risk. Mirtazapine's alpha-2 antagonism increases serotonin release; additional serotonergic drugs compound this effect. | Moderate — monitor for serotonin syndrome symptoms; combination with SSRIs is sometimes used therapeutically ("California rocket fuel" with venlafaxine) under close supervision |
| CYP3A4 inducers (carbamazepine, rifampin, phenytoin) | Mirtazapine is metabolized partly by CYP3A4; potent inducers significantly reduce plasma levels, potentially diminishing therapeutic effect. | Moderate — monitor for reduced efficacy; dose adjustment may be needed |
Warnings & Contraindications
Contraindications
- Concomitant use with MAO inhibitors, linezolid, or IV methylene blue
- Hypersensitivity to mirtazapine
Discontinuation
Mirtazapine discontinuation syndrome is generally milder than that of SSRIs, but abrupt stopping after prolonged use can cause rebound anxiety, insomnia, irritability, nausea, and dizziness. Taper gradually — slower tapers for patients on higher doses or those who have been on mirtazapine for extended periods.
Agranulocytosis Monitoring
Although rare, mirtazapine-associated agranulocytosis is a recognized risk. Patients should be instructed to promptly report any signs of infection — fever, chills, sore throat, mouth ulcers. If agranulocytosis is suspected, obtain a complete blood count immediately and discontinue mirtazapine.
Check for interactions between mirtazapine and your other medications.
Check Drug Interactions →Frequently Asked Questions
Does mirtazapine cause weight gain?
Yes — weight gain is one of the most common and clinically significant side effects of mirtazapine, and it is frequently substantial. The mechanism involves two converging effects: H1 (histamine-1) receptor blockade increases appetite and promotes fat storage, and 5-HT2C antagonism reduces satiety signaling. Many patients report dramatically increased appetite — particularly for carbohydrate-dense foods — starting within the first week of treatment. This effect can be therapeutically useful in patients who are underweight, malnourished, or experiencing appetite loss from cancer, chemotherapy, or HIV. For patients who are already overweight or who have metabolic syndrome, this is a major consideration when selecting an antidepressant.
Why is mirtazapine more sedating at lower doses?
This is one of the most counterintuitive pharmacology facts in psychiatry. At lower therapeutic levels, mirtazapine's H1 (histamine) receptor blockade dominates — histamine blockade causes profound sedation and is the same mechanism behind the drowsiness caused by antihistamines. At higher levels, mirtazapine more robustly activates the noradrenergic system (by blocking inhibitory alpha-2 autoreceptors), and norepinephrine has arousing, activating properties that partially counteract the sedation. The net result: lower levels = mostly H1 blockade = more sedation; higher levels = more noradrenergic activation = less net sedation. This is why increasing the dose sometimes paradoxically helps patients who are oversedated.
Is mirtazapine an SSRI?
No — mirtazapine is not an SSRI. It belongs to a different class called NaSSA (Noradrenergic and Specific Serotonergic Antidepressant). Instead of blocking the reuptake of serotonin like SSRIs (sertraline, fluoxetine, escitalopram), mirtazapine works by a completely different mechanism: it blocks presynaptic alpha-2 adrenergic autoreceptors, which disinhibits the release of both norepinephrine and serotonin, and it also blocks specific serotonin receptor subtypes (5-HT2A, 5-HT2C, 5-HT3) rather than preventing serotonin reuptake. These mechanistic differences translate into a distinct side effect profile: notably less sexual dysfunction and less nausea than SSRIs, but more sedation and weight gain.